$BLNC
Balance Labs, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223039091 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.370K $34.48K
YoY Change -93.27% 38.75%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.370K $34.48K
YoY Change -93.27% 38.73%
Operating Profit -$34.48K
YoY Change -180.85%
Interest Expense -$124.4K $57.51K
YoY Change -24.94% 0.0%
% of Operating Profit
Other Income/Expense, Net -$34.26K
YoY Change -81.51%
Pretax Income -$128.8K -$68.74K
YoY Change -34.41% -51.79%
Income Tax
% Of Pretax Income
Net Earnings -$128.8K -$68.74K
YoY Change -34.41% -51.79%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$0.01 $0.00
COMMON SHARES
Basic Shares Outstanding 21.67M shares 21.67M shares
Diluted Shares Outstanding 21.67M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $220.7K $324.3K
YoY Change -42.54% -37.06%
Cash & Equivalents $112.8K $145.6K
Short-Term Investments $107.9K $178.7K
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $0.00
Total Short-Term Assets $220.7K $324.3K
YoY Change -48.56% 3.22%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $220.7K $324.3K
Total Long-Term Assets $0.00 $0.00
Total Assets $220.7K $324.3K
YoY Change -48.56% -42.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.785M $2.271M
YoY Change 30.65% 149.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.699M $1.699M
YoY Change 0.0% 0.0%
Long-Term Debt Due $280.0K $280.0K
YoY Change 0.0% 0.0%
Total Short-Term Liabilities $4.764M $4.250M
YoY Change 15.89% 5.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $488.7K
YoY Change -100.0% 2.38%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $488.7K
YoY Change -100.0% 2.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.764M $4.250M
Total Long-Term Liabilities $0.00 $488.7K
Total Liabilities $4.764M $4.738M
YoY Change 3.77% 4.72%
SHAREHOLDERS EQUITY
Retained Earnings -$5.355M -$5.226M
YoY Change 7.67% 9.4%
Common Stock $2.167K $2.167K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.543M -$4.414M
YoY Change
Total Liabilities & Shareholders Equity $220.7K $324.3K
YoY Change -48.56% -42.06%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$128.8K -$68.74K
YoY Change -34.41% -51.79%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$32.81K -$36.78K
YoY Change -24.51% -172.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -32.81K -36.78K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -32.81K -36.78K
YoY Change -4.71% -187.63%
FREE CASH FLOW
Cash From Operating Activities -$32.81K -$36.78K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
BLNC Accreted Interest On Note Receivable
AccretedInterestOnNoteReceivable
usd
BLNC Equity Method Investment Summarized Financial Information Net Loss
EquityMethodInvestmentSummarizedFinancialInformationNetLoss
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001632121
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023Q3 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
usd
CY2023Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
usd
CY2023Q3 BLNC Accreted Interest Income And Interest Income On Note Receivable
AccretedInterestIncomeAndInterestIncomeOnNoteReceivable
usd
BLNC Accreted Interest Income And Interest Income On Note Receivable
AccretedInterestIncomeAndInterestIncomeOnNoteReceivable
usd
CY2023Q3 BLNC Bad Debt Expense On Note Receivable
BadDebtExpenseOnNoteReceivable
usd
BLNC Bad Debt Expense On Note Receivable
BadDebtExpenseOnNoteReceivable
usd
CY2023Q3 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
usd
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
usd
BLNC Amortization Of Expense On Note Receivable
AmortizationOfExpenseOnNoteReceivable
usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
usd
BLNC Increase Decrease In Accumulated Income Losses Of Unconsolidated Investees In Excess Of Investment
IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
usd
us-gaap Depreciation
Depreciation
usd
us-gaap Depreciation
Depreciation
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-202959
dei Entity Registrant Name
EntityRegistrantName
BALANCE LABS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1146785
dei Entity Address Address Line1
EntityAddressAddressLine1
407 Lincoln Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 701
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami Beach
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33139
dei City Area Code
CityAreaCode
(305)
dei Local Phone Number
LocalPhoneNumber
907-7600
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21674000 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145618 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
235311 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
45000 usd
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
178702 usd
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
148808 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
324320 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
429119 usd
CY2023Q3 us-gaap Assets
Assets
324320 usd
CY2022Q4 us-gaap Assets
Assets
429119 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1359481 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1220017 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4249740 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4110276 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
11340 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
19845 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
488660 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
480155 usd
CY2023Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
488660 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
480155 usd
CY2023Q3 us-gaap Liabilities
Liabilities
4738400 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4590431 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21674000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21674000 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2167 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
810048 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5226295 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4973527 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4414080 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324320 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429119 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
67500 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
202500 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
11274 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
10000 usd
us-gaap Professional Fees
ProfessionalFees
50249 usd
us-gaap Professional Fees
ProfessionalFees
85461 usd
CY2023Q3 us-gaap Salaries And Wages
SalariesAndWages
15200 usd
CY2022Q3 us-gaap Salaries And Wages
SalariesAndWages
10090 usd
us-gaap Salaries And Wages
SalariesAndWages
42141 usd
us-gaap Salaries And Wages
SalariesAndWages
43911 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34479 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
24854 usd
us-gaap Operating Expenses
OperatingExpenses
111926 usd
us-gaap Operating Expenses
OperatingExpenses
205432 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34479 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
42646 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-111926 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2932 usd
CY2023Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
23250 usd
CY2022Q3 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-73054 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
29894 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-304238 usd
CY2022Q3 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-287 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-43812 usd
CY2022Q3 BLNC Accreted Interest Income And Interest Income On Note Receivable
AccretedInterestIncomeAndInterestIncomeOnNoteReceivable
3555 usd
BLNC Accreted Interest Income And Interest Income On Note Receivable
AccretedInterestIncomeAndInterestIncomeOnNoteReceivable
11110 usd
CY2022Q3 BLNC Bad Debt Expense On Note Receivable
BadDebtExpenseOnNoteReceivable
141000 usd
BLNC Bad Debt Expense On Note Receivable
BadDebtExpenseOnNoteReceivable
141000 usd
CY2022Q3 us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
83064 usd
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
83064 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
57506 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
57507 usd
us-gaap Interest Expense
InterestExpense
170736 usd
us-gaap Interest Expense
InterestExpense
174164 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34256 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-185229 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-140842 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-569040 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-68735 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-142583 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
us-gaap Net Income Loss
NetIncomeLoss
-571972 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21674000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21674000 shares
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4345345 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-68735 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4414080 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3822350 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-142583 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3964933 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4161312 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-4414080 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3392961 usd
us-gaap Net Income Loss
NetIncomeLoss
-571972 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3964933 usd
us-gaap Net Income Loss
NetIncomeLoss
-252768 usd
us-gaap Net Income Loss
NetIncomeLoss
-571972 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8505 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
11933 usd
BLNC Amortization Of Expense On Note Receivable
AmortizationOfExpenseOnNoteReceivable
3309 usd
BLNC Equity Method Investment Summarized Financial Information Net Loss
EquityMethodInvestmentSummarizedFinancialInformationNetLoss
43812 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
29894 usd
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-304524 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
141000 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
83064 usd
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-45000 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
9026 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
139464 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
147058 usd
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
60000 usd
BLNC Increase Decrease In Accumulated Income Losses Of Unconsolidated Investees In Excess Of Investment
IncreaseDecreaseInAccumulatedIncomeLossesOfUnconsolidatedInvesteesInExcessOfInvestment
1226 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89693 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
42182 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-89693 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42182 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
235311 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
227558 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
145618 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
269740 usd
us-gaap Interest Paid Net
InterestPaidNet
27218 usd
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
178702 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89693 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
145618 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5226295 usd
CY2023Q3 BLNC Working Capital Deficit
WorkingCapitalDeficit
-3925420 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
2000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zz6jHqGwMRh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_860_zTmvNh9lTmpc">Use of Estimates</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates may include those pertaining to stock-based compensation, depreciable lives of fixed assets and deferred tax assets. Actual results could materially differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
148808 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
11340 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
19845 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
488660 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
480155 usd
CY2022Q4 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
1000000 shares
CY2022Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1000000 usd
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.00
CY2023Q3 us-gaap Investment Owned Balance Shares
InvestmentOwnedBalanceShares
66432 shares
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
2.69
us-gaap Debt Securities Unrealized Gain Loss
DebtSecuritiesUnrealizedGainLoss
29894 usd
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1 share for 8 share reverse stock split
CY2023Q3 us-gaap Investments
Investments
0 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84D_eus-gaap--ConcentrationRiskCreditRisk_zKTZuTfe3am3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline"><span id="xdx_869_zVxiiZr51ITc">Concentration of Credit Risk</span></span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and marketable securities. As of September 30, 2023, and December 31, 2022, the carrying value of marketable securities was $<span id="xdx_90F_eus-gaap--MarketableSecurities_iI_pp0p0_c20230930_zBQHNEs2W6ed" title="Marketable securities">178,702</span> and $<span id="xdx_900_eus-gaap--MarketableSecurities_iI_pp0p0_c20221231_zLNWGcWvez02" title="Marketable securities">148,808</span>, respectively. The securities are included in the Investment at Fair Value – Related Party on the consolidated balance sheets, which consist of common shares held in one (1) investment which currently is trading on the Over-the-Counter Bulletin Board (OTCBB).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 integer
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
6785 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
48 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
4392 usd
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
48 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11316 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11316 usd
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 BLNC Notes Receivable Unamortized Allowance Current Percentage
NotesReceivableUnamortizedAllowanceCurrentPercentage
1 pure
CY2023Q3 BLNC Notes Receivable Unamortized Allowance Current
NotesReceivableUnamortizedAllowanceCurrent
141000 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
106850 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
106850 usd
CY2023Q3 BLNC Due To Related Party Current
DueToRelatedPartyCurrent
173192 usd
CY2022Q4 BLNC Due To Related Party Current
DueToRelatedPartyCurrent
173192 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11340 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
19845 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
488660 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
480155 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
11340 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
19845 usd
CY2023Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
488660 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
480155 usd

Files In Submission

Name View Source Status
0001493152-23-039091-index-headers.html Edgar Link pending
0001493152-23-039091-index.html Edgar Link pending
0001493152-23-039091.txt Edgar Link pending
0001493152-23-039091-xbrl.zip Edgar Link pending
blnc-20230930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
blnc-20230930_def.xml Edgar Link unprocessable
blnc-20230930_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
blnc-20230930_cal.xml Edgar Link unprocessable
blnc-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable